Bacillus Calmette Guerin Vaccine

Pharmacologic Category

Vaccine; Vaccine, Live (Bacterial)

Dosing: Adult

Note: Dosing and administration based on US percutaneous product (TICE strain); formulation/dosing/route may vary in other regions (consult local product labeling).

Immunization against tuberculosis: Percutaneous: 0.2 to 0.3 mL (full-strength dilution); conduct postvaccinal tuberculin test in 2 to 3 months; if test is negative, repeat vaccination. Note: Initial lesions usually appear after 10 to 14 days and consist of small, red papules at injection site, which reach maximum diameter of 3 mm in 4 to 6 weeks.

Prevention of leprosy (off-label use): Percutaneous: 0.2 to 0.3 mL (full-strength dilution); a single dose offers partial protection against leprosy; an additional dose may confer greater protection, however, studies do not specify appropriate interval (Bertolli 1997; Karonga Prevention Trial Group 1996; Setia 2006; Zodpey 2007). Note: Timing of vaccination and chemoprophylaxis should be taken into consideration since chemoprophylaxis may kill BCG (Rodrigues 2011).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

Note: Dosing and administration based on US percutaneous product (TICE strain); formulation/dosing/route may vary in other regions (consult local product labeling). According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Ezeanolue 2020]).

Immunization against tuberculosis: Infants, Children, and Adolescents: Percutaneous: Full-strength: 0.2 to 0.3 mL as a single dose; conduct postvaccinal tuberculin test in 2 to 3 months; if test is negative, repeat vaccination (at age ≥1 year). Note: Initial lesion usually appears after 10 to 14 days consisting of small, red papule at injection site and reaches maximum diameter of 3 mm in 4 to 6 weeks.

Leprosy, prophylaxis in areas with high incidence: Limited data available (Setia 2006; Zodbey 2007): Infants, Children, and Adolescents with no evidence of immunity: Percutaneous: Full-strength: 0.2 to 0.3 mL as a single dose (WHO 2017)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Use: Labeled Indications

Mycobacterium tuberculosis disease prevention: Active immunization against Mycobacterium tuberculosis in persons not previously infected and who are at high risk for exposure

BCG vaccine is not routinely administered for the prevention of M. tuberculosis in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination be considered for the following (CDC/ACIP [Villarino 1996]):

- Infants and children with a negative tuberculin skin test who are continually exposed to (and cannot be separated from) patients who are untreated or ineffectively treated for infectious pulmonary TB disease when the child cannot be given long-term treatment for infection or if the patient has infectious pulmonary TB caused by strains resistant to isoniazid and rifampin.

- Health care workers with a high percentage of patients with M. tuberculosis strains resistant to both isoniazid and rifampin, if there is ongoing transmission of the resistant strains and subsequent infection is likely, or if comprehensive infection-control precautions have not been successful. In addition, health care workers should be counseled on the risks and benefits of vaccination and treatment of latent TB infection

The Advisory Council for the Elimination of Tuberculosis (ACET) recommends BCG vaccination for health care and humanitarian workers who travel to work where the incidence of multidrug-resistant tuberculosis is high and potential transmission may occur. The ACET recommends a set of risk-reduction measures for such workers, noting that interferon-gamma release assays can differentiate tuberculosis infection from BCG vaccination effect (Seaworth 2014).

Use: Off-Label: Adult

​Prevention of leprosyLevel of Evidence [B]

Evidence from controlled trials and meta-analyses of controlled trials, cohort studies, and case-control studies indicates that use of BCG vaccine is partially protective against leprosy. Data are limited by high levels of heterogeneity for experimental trials and case-control studies Ref. Access Full Off-Label Monograph

Level of Evidence Definitions

​Level of Evidence Scale

Clinical Practice Guidelines

ACIP, "General Best Practice Guidelines for Immunization," April 2017

IDSA, "Vaccination of the Immunocompromised Host," 2013

NACI/CATMAT, Canadian Immunization Guide, 2017

Administration: Other

Note: Administration based on US percutaneous product (TICE strain); formulation/dosing/route may vary in other regions around the globe (consult local product labeling).

Should only be given percutaneously; do not administer IV, SubQ, IM, or intradermally. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Ezeanolue 2020]).

Apply vaccine with syringe and needle by dropping onto 1 to 2 inch area of horizontally positioned surface of cleansed, dry site (deltoid region of arm preferred); pulling skin tight, puncture skin with multiple puncture device centered over the vaccine; apply pressure for 5 seconds (do not "rock" device). After successful puncture, spread vaccine evenly using the edge of the device over puncture area; an additional 1 to 2 drops of vaccine may be added to ensure a very wet vaccination site. Apply loose covering and keep dry for 24 hours.

When used for immunization against tuberculosis, US federal law requires that the name of medication, date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.

Administration: Pediatric

Note: Administration based on US percutaneous product (TICE strain); formulation/dosing/route may vary in other regions (consult local product labeling).

Percutaneous: Should only be given percutaneously; do not administer IV, SubQ, IM, or intradermally. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Ezeanolue 2020]). Apply vaccine with syringe and needle by dropping onto 1- to 2-inch area of horizontally positioned surface of cleansed, dry site (deltoid region of arm preferred); pulling skin tight, puncture skin with multiple puncture device centered over the vaccine; apply pressure for 5 seconds (do not “rock” device). After successful puncture, spread vaccine evenly using the edge of the device over puncture area; an additional 1 to 2 drops of vaccine may be added to ensure a very wet vaccination site. Apply loose covering and keep dry for 24 hours. When used for immunization against tuberculosis, US federal law requires that the name of medication; date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record. Multiple puncture device for vaccination available from Organon Teknika (1-800-662-6842).

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving and a gown are required during administration (NIOSH 2016).

Storage/Stability

Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from sunlight. Store reconstituted vaccine in refrigerator; use within 2 hours of mixing. Do not freeze vaccine after reconstitution.

Preparation for Administration: Adult

Prepare using aseptic technique. Do not prepare parenteral medications in an area where BCG has been prepared. Do not filter. Reconstitute with 1 mL of SWFI; swirl gently, do not vigorously shake.

Preparation for Administration: Pediatric

Parenteral: Percutaneous: Prepare using aseptic technique. Do not prepare parenteral medications in an area where BCG has been prepared. Do not filter. Must be used within 2 hours of reconstitution.

Full-strength: Reconstitute with 1 mL of SWFI; swirl gently, do not vigorously shake

Half-strength dilution: Neonates: Reconstitute with 2 mL SWFI, swirl gently, do not vigorously shake

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to prevent TB (tuberculosis).

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Loss of strength and energy

• Swollen glands

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Flu-like symptoms longer than 2 days

• Bone pain

• Severe fever

• Skin ulcers

• Severe injection site irritation, redness, pain, or swelling

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Medication Safety Issues

​Sound-alike/look-alike issues:

Contraindications

Prior hypersensitivity to the vaccine or any component of the formulation; immunosuppressed patients or persons with congenital or acquired immune deficiencies (eg, HIV infection, leukemia, lymphoma, cancer therapy, immunosuppressive therapy such as corticosteroids); active tuberculosis

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Ezeanolue 2020]).

• BCG reaction: Local adverse effects may include moderate axillary or cervical lymphadenopathy and induration/pustule formation at the injection site; lasting as long as 3 months or more. Severe ulceration, regional suppurative lymphadenitis with draining sinuses, and caseous lesions or purulent drainage may occur within 5 months and persist for several weeks. Systemic adverse effects lasting 1 to 2 days and similar to a flu-like syndrome (fever, anorexia, myalgia, and neuralgia) are generally caused by hypersensitivity to the vaccine.

• Disseminated infections: May cause BCG infection, particularly in immunocompromised patients. If signs and symptoms of a systemic BCG infection occur (eg, fever of ≥103°F or acute local reactions lasting longer than 2 to 3 days), permanently discontinue BCG vaccination and begin therapy with ≥2 antimycobacterial agents while conducting a diagnostic evaluation. Infection from vaccine is not sensitive to pyrazinamide. BCG osteomyelitis affecting the epiphyses of the long bones is the most common disseminated infection and may occur 4 months to 2 years after vaccination.

• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Ezeanolue 2020]).

Disease-related concerns:

• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Ezeanolue 2020]).

• HIV: Use is contraindicated in HIV-infected persons (ACIP [Ezeanolue 2020]). Should be administered with caution to persons in groups at high risk for HIV. HIV-infected persons thought to be infected with Mycobacterium tuberculosis should be strongly recommended for tuberculosis preventive therapy.

Concurrent drug therapy issues:

• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, >1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Ezeanolue 2020]).

Special populations:

• Altered immunocompetence: Use is contraindicated in immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]). Household and close contacts of persons with altered immunocompetence may receive most age appropriate vaccines (ACIP [Ezeanolue 2020]). Live vaccines should be administered ≥4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Ezeanolue 2020]; (IDSA [Rubin 2014]).

• Positive PPD reaction: Determine PPD status prior to use. BCG vaccination is not recommended for persons with a positive PPD reaction.

Special handling:

• Biohazard agent: Contains live, attenuated mycobacteria. Use appropriate precautions for handling and disposal. BCG is a biohazard; proper preparation technique, handling, and disposal of all equipment in contact with BCG as a biohazard material is recommended. BCG infections have been reported in healthcare workers due to accidental exposure (needlestick, skin laceration); nosocomial infections have been reported in patients receiving parenteral medications prepared in areas where BCG was prepared. To avoid cross contamination, do not prepare parenteral medications in an area where BCG has been prepared.

Other warnings/precautions:

• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Ezeanolue 2020]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).

• Appropriate use: BCG vaccine should not be used for the active treatment of tuberculosis.

• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Ezeanolue 2020]).

Reproductive Considerations

In general, women should avoid conception for 4 weeks after vaccination with live vaccines (ACIP [Ezeanolue 2020]).

Pregnancy Considerations

Animal reproduction studies have not been conducted. BCG vaccine is not recommended for use in pregnant women. Because of the theoretical risk to the fetus, women known to be pregnant generally should not receive live, attenuated virus vaccines (ACIP [Ezeanolue 2020]).

Breast-Feeding Considerations

It is not known if BCG vaccine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breastfeeding or avoid use of BCG vaccine, taking into account the importance of BCG vaccination to the mother.

Briggs' Drugs in Pregnancy & Lactation

• Vaccine, BCG

Adverse Reactions

Local reactions may persist for up to 3 months; more severe manifestations may occur up to 5 months after vaccination and persist for several weeks.

Frequency not defined:

Dermatologic: Pustules (at injection site), skin ulceration at injection site

Hematologic & oncologic: Cervical lymphadenopathy, lymphadenitis (includes local and suppurative), lymphadenopathy (axillary)

Infection: BCG infection (BCG osteomyelitis; may occur from 4 months to 2 years after vaccination)

Local: Induration at injection site, injection site lesion, itching at injection site, tenderness at injection site

Respiratory: Flu-like symptoms

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Antibiotics: May diminish the therapeutic effect of BCG Vaccine (Immunization). Exceptions: Acetic Acid (Otic); Acetic Acid (Topical); Aluminum Acetate; Azithromycin (Ophthalmic); Aztreonam (Oral Inhalation); Bacitracin (Ophthalmic); Bacitracin (Topical); Chlortetracycline; Ciprofloxacin (Ophthalmic); Clindamycin (Topical); Dapsone (Topical); Dibrompropamidine (Ophthalmic); Dibrompropamidine (Topical); Erythromycin (Ophthalmic); Erythromycin (Topical); Fidaxomicin; Framycetin; Fusidic Acid (Ophthalmic); Fusidic Acid (Topical); Gatifloxacin; Gentamicin (Ophthalmic); Gentamicin (Topical); MetroNIDAZOLE (Topical); Mupirocin; Nitrofurazone; Ozenoxacin; Sulfacetamide (Ophthalmic); Tobramycin (Ophthalmic). Risk C: Monitor therapy

AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided. Risk D: Consider therapy modification

Belimumab: May enhance the adverse/toxic effect of Vaccines (Live). Risk X: Avoid combination

Brexucabtagene Autoleucel: May enhance the adverse/toxic effect of Vaccines (Live). Brexucabtagene Autoleucel may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone >2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines prior to therapy whenever possible. Exceptions: Deflazacort. Risk D: Consider therapy modification

Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Deflazacort: May enhance the adverse/toxic effect of Vaccines (Live). Deflazacort may diminish the therapeutic effect of Vaccines (Live). Management: Administer all vaccines according to immunization guidelines prior to initiating deflazacort. Live vaccines should be administered at least 4 to 6 weeks prior to initiating deflazacort. Risk D: Consider therapy modification

Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Non-US labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment. US labeling states that safety and effectiveness of live vaccines administered with dimethyl fumarate has not been assessed. Risk C: Monitor therapy

Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live). Risk X: Avoid combination

Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Guselkumab: May enhance the adverse/toxic effect of Vaccines (Live). Risk X: Avoid combination

Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Consult full interaction monograph for dose interval recommendations. This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions. Risk D: Consider therapy modification

Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Exceptions: AzaTHIOprine; Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Deflazacort; DexAMETHasone (Systemic); Fludrocortisone; Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic). Risk X: Avoid combination

Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide. Risk D: Consider therapy modification

Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided. Risk D: Consider therapy modification

Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided. Risk D: Consider therapy modification

Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin. Risk D: Consider therapy modification

Risankizumab: May enhance the adverse/toxic effect of Vaccines (Live). Risk X: Avoid combination

Tildrakizumab: May enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests. Management: If a parenteral live vaccine has been recently administered, do administer a scheduled PPD skin test for at least 4-6 weeks following administration of the vaccine. Simultaneous administration of a parenteral live vaccine and PPD skin test is acceptable. Risk D: Consider therapy modification

Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later. Exceptions: Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine. Risk C: Monitor therapy

Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment. Risk X: Avoid combination

Test Interactions

PPD intradermal test: BCG results in reactive tuberculin skin test; rule out active tuberculosis prior to initiating intravesicular BCG treatment. BCG vaccine may be administered to persons with a PPD reaction of <5 mm induration; PPD should be used again 2 to 3 months after vaccination to ensure reactivity to vaccine (document in mm of induration). Vaccinees with a positive PPD test (>5 mm) should not be tested again unless exposed to tuberculosis. In this situation, an increase of induration may indicate a newly acquired TB infection. Vaccinees with a negative PPD test (<5 mm induration) may continue periodic skin testing as long as the results remain <5 mm (CDC/ACIP, [Villarino 1996]).

Interferon-gamma release assay (IGRA) tests for latent TB infection (LTBI) are not affected by BCG vaccination history and are considered acceptable for monitoring occupational exposures in healthcare workers (Mazurek 2010).

Monitoring Parameters

PPD test prior to vaccination. Flu-like symptoms ≥72 hours, fever ≥103°F, acute local reactions lasting >2 to 3 days. Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Ezeanolue 2020]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Injectable, Injection:

Generic: 50 mg (1 ea)

Anatomic Therapeutic Chemical (ATC) Classification

• J07AN01

Generic Available (US)

Yes

Mechanism of Action

BCG vaccine is an attenuated, live bacterial culture of the Bacillus of Calmette and Guérin (BCG) strain of Mycobacterium bovis and induces active immunity against Mycobacterium tuberculosis.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Centers for Disease Control and Prevention (CDC) and Other Links
• Immunization Administration Recommendations
• Immunization Schedules
• Safe Handling of Hazardous Drugs

Index Terms

Bacillus Calmette-Guérin (BCG) Live; BCG Vaccine U.S.P. (percutaneous use product); BCG, Live

References

Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and e-ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

BCG vaccine [prescribing information]. Durham, NC: Organon USA; September 2014.

Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol. 1997;26(4):888-896. doi:10.1093/ije/26.4.888[PubMed 9279624]

Centers for Disease Control and Prevention (CDC). Fact Sheets: BCG Vaccine. October 2011. Available at http://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm

Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199.[PubMed 6423951]

Centers for Disease Control and Prevention. TB elimination: BCG vaccine. November 2008. Available at http://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm

Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed March 18, 2020.

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348(9019):17-24.[PubMed 8691924]

Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(5):136-138.[PubMed 28182599]

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010;59:1–25.[PubMed 20577159]

Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines. 2010;9(2):209-222. doi:10.1586/erv.09.161[PubMed 20109030]

Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339-1350.[PubMed 19837254]

Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(5):134-135.[PubMed 28182607]

Rodrigues LC, Lockwood DNj. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11(6):464-470. doi: 10.1016/S1473-3099(11)70006-8.[PubMed 21616456]

Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-e100.[PubMed 24311479]

Seaworth BJ, Armitige LY, Aronson NE, Hoft DF, Fleenor ME, et al. Multidrug-resistant tuberculosis: Recommendations for reducing risk during travel for healthcare and humanitarian work. Ann Am Thorac Soc. 2014;11:286-295. doi: 10.1513/AnnalsATS.201309-312PS.[PubMed 24673692]

Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6(3):162-170. doi:10.1016/S1473-3099(06)70412-1[PubMed 16500597]

Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.

Villarino ME. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP). The role of BCG vaccine in the prevention and control of tuberculosis in the United States: A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep, 1996, 45(RR-4):1-18. Available at http://www.cdc.gov/mmwr/PDF/rr/rr4504.pdf[PubMed 8602127]

WHO SAGE Working Group. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. September 22, 2017. Available at http://www.who.int/immunization/sage/meetings/2017/october/1_BCG_report_revised_version_online.pdf. Date accessed November 2, 2017.

Zodpey SP. Protective effect of bacillus Calmette Guérin (BCG) vaccine in the prevention of leprosy: a meta-analysis. Indian J Dermatol Venereol Leprol. 2007;73(2):86-93. doi:10.4103/0378-6323.31891[PubMed 17456912]

Last Updated 9/2/20